Back to Journals » International Journal of General Medicine » Volume 2

Screening of potential molecular targets for colorectal cancer therapy

Authors Honma K, Takemasa I, Matoba R, Yamamoto Y, Takeshita F, Mori M, Monden M, Matsubara K, Ochiya T

Published 18 November 2009 Volume 2009:2 Pages 243—257


Review by Single anonymous peer review

Peer reviewer comments 3

Kimi Honma1, Ichiro Takemasa2, Ryo Matoba3, Yusuke Yamamoto1, Fumitaka Takeshita1, Masaki Mori2, Morito Monden2, Kenichi Matsubara3, Takahiro Ochiya1

1Section for Studies on Metastasis, National Cancer Center Research Institute, Tokyo, Japan; 2Graduate School of Medicine, Osaka University, Osaka, Japan; 3DNA Chip Research Inc., Yokohama, Japan

Abstract: Colorectal cancer is a leading cause of cancer death worldwide. To identify molecular targets for colorectal cancer therapy, we tested small interfering RNAs (siRNAs) against 97 genes whose expression was elevated in human colorectal cancer tissues for the ability to promote apoptosis of human colorectal cancer cells (HT-29 cells). The results indicate that the downregulation of PSMA7 (proteasome subunit, α-type, 7) and RAN (ras-related nuclear protein) most efficiently induced apoptosis of HT-29 cells. PSMA7 and RAN were highly expressed in colorectal cancer cell lines compared with normal colon tissues. Furthermore, PSMA7 and RAN were overexpressed in not only colon tumor tissues but also the other tumor tissues. Moreover, in vivo delivery of PSMA7 siRNA and RAN siRNA markedly induced apoptosis in HT-29 xenograft tumors in mice. Thus, silencing of PSMA7 and RAN induces cancer cells to undergo apoptosis, and PSMA7 and RAN might be promising new molecular targets for drug and RNA interference-based therapeutics against colorectal cancer.

Keywords: colorectal cancer, molecular target, RNAi, PSMA7, RAN

Creative Commons License © 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.